No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AXSM241220P65000
- 0.35
- 0.000.00%
15min DelayTrading Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.35Pre Close0 Volume683 Open Interest65.00Strike Price0.00Turnover0.00%IV23.03%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-10DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma239.97Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180
HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy